Surena F. Matin, MD, presented “Mitomycin Gel (UGN-101) Approved for Treating Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial” for the Grand Rounds in Urology audience in April, 2020.
How to cite: Matin, Surena F. “Mitomycin Gel (UGN-101) Approved for Treating Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial” April, 2020. Accessed May 2021. https://grandroundsinurology.com/mitomycin-gel-ugn-101-approved-for-treating-low-grade-upper-tract-urothelial-carcinoma-the-olympus-trial/
Mitomycin Gel (UGN-101) Approved for Treating Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial – Summary:
Correction by Dr. Matin: Jelmyto is considered a drug, not a drug device as stated in this video.
Surena F. Matin, MD, Professor in the Department of Urology at MD Anderson Cancer Center in Houston, Texas, discusses the OLYMPUS Trial which studied the effects of mitomycin gel (UGN-101) in treating low-grade upper tract urothelial carcinoma. The FDA has recently approved this drug for treatment after the trial’s successful results. Prior to approval, there was no method of treatment that allowed for topical therapies in upper-tract cancer cases like there is for the bladder, and there had been little research into potential treatments. Dr. Matin was an investigator on the trial and discusses the selection of participants, the procedures of the trial, and the conclusions that were drawn. He highlights that during the trial, 58% of participants had a complete response, and that fully optimizing the drug plays an important role in those high numbers of success. He also discusses some of the adverse events that occurred during the trial and considerations for using mitomycin gel as a treatment.
For more information on upper tract urothelial carcinoma, please visit our Next-Generation Learning Center on this topic.